Summary
IDEXX Laboratories, Inc. (IDXX) filed an 8-K report on November 15, 2016, detailing a significant executive departure. Michael Williams, Ph.D., Executive Vice President, stepped down from his role effective November 9, 2016, and will be leaving the company in February 2017. His transition will be supported through continued employment until February 28, 2017. In connection with his departure, the company has entered into an agreement with Dr. Williams, which includes a lump sum payment of $460,000 and a further payment of $450,000 distributed over bi-weekly installments. This arrangement is contingent upon Dr. Williams' adherence to non-competition and non-solicitation covenants, as well as a standard release of claims. Investors should note this change in senior leadership and the financial implications of the separation agreement.
Key Highlights
- 1Executive Vice President Michael Williams, Ph.D., is departing the company.
- 2Dr. Williams stepped down from his current role on November 9, 2016.
- 3His departure from the company is scheduled for February 2017, with a transition period until February 28, 2017.
- 4IDEXX has agreed to a separation package for Dr. Williams.
- 5The package includes a $460,000 lump sum payment.
- 6An additional $450,000 will be paid in bi-weekly installments.
- 7The payments are conditional on Dr. Williams' compliance with non-competition and non-solicitation agreements, and a release of claims.